Arrowhead Pharmaceuticals, Inc. is a biotech company developing new medicines.
Arrowhead Pharmaceuticals, Inc. (ARWR) is expected to report earnings on Tuesday, November 24, 2026, after the close. Estimated release time 16:06 ET. Consensus EPS estimate is $-1.59.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | Jun 2026 qtr | $-1.28 | $-1.36 | -6.3% | $75.25M |
| 2026-05-07 | Mar 2026 qtr | $-1.09 | $-0.93 | +14.7% | $73.74M |
| 2026-02-05 | Dec 2025 qtr | $0.60 | $0.22 | — | $264.03M |
| 2025-11-25 | Sep 2025 qtr | $-0.11 | $-0.17 | — | $256.47M |
| 2025-02-10 | Dec 2024 qtr | $-0.42 | $-1.39 | — | $2.50M |
| 2024-08-08 | Jun 2024 qtr | $-0.58 | $-1.38 | — | $0 |
| 2024-05-09 | Mar 2024 qtr | $-0.06 | $-1.02 | — | $0 |
| 2024-02-06 | Dec 2023 qtr | $-0.78 | $-1.24 | — | $3.55M |
ARWR has beaten consensus EPS in 1 of its last 2 scored quarters.
See ARWR on the live calendar →